Sara Toftegaard Hjuler

Sara Toftegaard Hjuler is an experienced professional in the field of pharmacology and translational medicine, currently serving as Director of Microphysiological Systems at Novo Nordisk since March 2018, where responsibilities include in vivo pharmacology within liver disease research. Prior to this role, Sara worked at Nordic Bioscience A/S from May 2011 to February 2018, contributing as a Scientist in Fibrosis and NASH Biology, managing projects focused on NAFLD/NASH, clinical and preclinical studies, and the development of biomarkers. Sara's academic background includes a PhD in Pharmacology and a Master of Science in Biology-Biotechnology, both obtained from the University of Copenhagen, alongside earlier education at Haslev Gymnasium & HF.